Tradestie Institutional Equity Comparison Engine

EDIT vs EPRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EPRX Overall Edge

EPRX Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) driven by superior Growth & Margin, Momentum & Technical while EDIT counters with relative strength in Options & Structure. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus EPRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against EPRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EDIT N/M vs EPRX N/M Fwd P/E
Growth & Margin Winner EPRX
Op Margin -167.0% vs 0.0% ยท YoY +37.4% vs +0.0%
Momentum & Technical Winner EPRX
1Y -25.0% vs +17.7% ยท 52W Pos 11% vs 50%
Options & Structure Winner EDIT
BREAKDOWN (38th %ile IV) vs UNCLASSIFIED (N/A IV)
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
1M Return -18.94%
1Y Return -25.0%
Forward P/E N/M
Unified AI Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
EPRX NASDAQ
Eupraxia Pharmaceuticals Inc. Common Stock
Pharmaceutical Preparations
$7.46
-8.47% 1D
Market Cap $525.4M
1M Return +12.69%
1Y Return +17.67%
Forward P/E N/M
Unified AI Score
34.1 / 100 SELL
Tech 15.0 Fund 40.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EDIT -25.0% EPRX +17.67% Spread: +42.67 pp (EPRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EDIT TTM Op. Margin: -167.0% EPRX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EDIT vs EPRX. Trailing 12-month operating profitability (EDIT -167.0% vs EPRX 0.0%) and valuation multiples (EDIT N/M vs EPRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EDIT (2) vs EPRX (6)
Institutional Metric EDIT EPRX Criterion Row Winner
Market Capitalization Scale $336.5M $525.4M Larger Scale EPRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +37.4% +0.0% Higher Growth EDIT
Operating Margin (TTM) Profitability -167.0% 0.0% Higher Margin EPRX
Net Profit Margin Profitability -144.9% 0.0% Higher Margin EPRX
Return on Equity (ROE) Capital Efficiency -147.4% -56.4% Higher ROE EPRX
52-Week Range Position Momentum 11% ($2โ€“$4) 50% ($6โ€“$9) Stronger Trend EPRX
Beta / 30D Volatility Risk Regime 2.32ฮฒ ยท 102% Vol 1.70ฮฒ ยท 77% Vol Lower Realized Risk EPRX
Unified Institutional Score Composite Signal 51.6 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite EDIT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EDIT vs EPRX Buy Guide
EDIT BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EDIT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EPRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EPRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EDIT nor EPRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.